TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin. Antioxidant supplementation has been proposed to reduce the side effects. H...

Full description

Bibliographic Details
Main Authors:	Yun Sun Lee, Young Joon Choi, JeeYun Lee, Da Mi Shim, Woong-Yang Park, Sung Wook Seo
Format:	Article
Language:	English
Published:	IOS Press 2017-06-01
Series:	Tumor Biology
Online Access:	https://doi.org/10.1177/1010428317700159

Similar Items

TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy
by: Yun Sun Lee, et al.
Published: (2018-08-01)

Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis
by: Marilanda Ferreira Bellini, et al.
Published: (2012-01-01)

TP53 and MDM2 alterations in human bladder cancer
by: Abdel-Fattah, Rana
Published: (1997)

Alterations of tumour protein 53 (TP53) pathways in diffuse large B-cell lymphomas
by: Magdi Abdel-Azim, Dalia
Published: (2009)

The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
by: Lawrence A. Donehower, et al.
Published: (2019-07-01)

Progress of TP53 Family Gene TP73 and Tumorigenesis
by: XU Jie, et al.
Published: (2021-02-01)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
by: Dmitriy Sonkin
Published: (2015-10-01)

Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
by: Elisabeth Silden, et al.
Published: (2013-01-01)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
by: Miguel Quijada‐Álamo, et al.
Published: (2021-02-01)

TP53 and c-myc Co-alterations: A hallmark of oral cancer progression
by: Tanić Nasta, et al.
Published: (2013-01-01)

TP53 Gene Alterations including Codon 72 Polymorphism in Patients with Multiple Myeloma
by: Perumal Govindasamy, et al.
Published: (2018-02-01)

TP53 in Biology and Treatment of Osteosarcoma
by: Kamil Jozef Synoradzki, et al.
Published: (2021-08-01)

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
by: Magali Olivier, et al.
Published: (2007-02-01)

The functions of non-coding TP53 RNA in cancer cells
by: Yi Syuan Lee, et al.
Published: (2019)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
by: Xuerui Li, et al.
Published: (2020-07-01)

Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.
by: Keith R Loeb, et al.
Published: (2012-01-01)

HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA
by: Siho Kim, et al.
Published: (2017-03-01)

TP53 PATHOGENIC VARIANTS RELATED TO CANCER
by: Rosero C.Y., et al.
Published: (2019-12-01)

KRAS and TP53 mutations in colorectal carcinoma
by: Al-Kuraya Khawla
Published: (2009-01-01)

TP53 mutation and cell cycle regulation
by: Wrighton, Katharine Helen
Published: (2004)

Utility of TP53 in Breast Carcinoma Immunophenotypes
by: Ria Jaggi, et al.
Published: (2020-09-01)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
by: Hye Jung Hwang, et al.
Published: (2020-09-01)

Inherited TP53 Variants and Risk of Prostate Cancer
by: Abida, W., et al.
Published: (2022)

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
by: Ellen C. Moore, et al.
Published: (2018-07-01)

Arctigenin Enhances the Cytotoxic Effect of Doxorubicin in MDA-MB-231 Breast Cancer Cells
by: Kyu-Shik Lee, et al.
Published: (2020-04-01)

O-GlcNAc Transferase Inhibitor Synergistically Enhances Doxorubicin-Induced Apoptosis in HepG2 Cells
by: Su Jin Lee, et al.
Published: (2020-10-01)

Expression signatures of <it>TP53 </it>mutations in serous ovarian cancers
by: Murphy Susan K, et al.
Published: (2010-05-01)

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
by: Meis Omran, et al.
Published: (2020-01-01)

Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles
by: Stephanie Antoun, et al.
Published: (2018-01-01)

Mechanisms of silencing TP53 in EBV - related neoplasias
by: Mariana Jorge de Oliveira Cardoso Denis Malta
Published: (2019)

TP53 structural variants in metastatic prostatic carcinoma.
by: Deepika Sirohi, et al.
Published: (2019-01-01)

Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
by: Sanjay Awasthi
Published: (2021-01-01)

TP53 mutations on circulating cell-free DNA
by: Klaus Pantel
Published: (2016-08-01)

TP53 and Beta-catenin mutations in liver tumours
by: Pierre Hainaut
Published: (2007-02-01)

TP53/MicroRNA Interplay in Hepatocellular Carcinoma
by: Daniela Pollutri, et al.
Published: (2016-12-01)

Regulators of Oncogenic Mutant TP53 Gain of Function
by: Satomi Yamamoto, et al.
Published: (2018-12-01)

TP53 Status and Response to Treatment in Breast Cancers
by: Mariana Varna, et al.
Published: (2011-01-01)

BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.
by: Heather R Shive, et al.
Published: (2014-01-01)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
by: Katarina K. Jovanović, et al.
Published: (2019-01-01)